Glutathione — Apex Research Reference

01 / IDENTITY

Compound Profile

3

AMINO ACIDS

~0.31

kDa MW

IV / SC / Neb

ROUTES

~2–4h

IV HALF-LIFE

~10 mM

INTRACELLULAR CONC

STRUCTURE

γ-Glu — Cys — Gly
The cysteine thiol group (-SH) is the active antioxidant site. The γ-glutamyl bond is unusual — it protects GSH from peptidase degradation, extending intracellular half-life.

ORIGIN — ENDOGENOUS MOLECULE

Glutathione is not a foreign compound — it is produced by every cell in the human body via two-step enzymatic synthesis (glutamate + cysteine → γ-glutamylcysteine; + glycine → GSH). Highest concentrations in liver hepatocytes (~10 mM). Declines 1% per year after age 20 — by age 60, intracellular GSH is 30–40% below youthful levels.

MECHANISM — MASTER REDOX REGULATOR

GSH is the cell's primary electron donor for neutralizing reactive oxygen species (ROS). The thiol group donates an electron to neutralize free radicals → GSH becomes oxidized glutathione (GSSG) → glutathione reductase regenerates GSH using NADPH. This GSH/GSSG cycle is the foundation of cellular antioxidant defense.

WHY ORAL GLUTATHIONE FAILS

Oral GSH is hydrolyzed in the GI tract by gamma-glutamyltransferase before absorption — the peptide bond is cleaved and individual amino acids are absorbed, not intact GSH. IV, SC, nebulized, or liposomal forms bypass GI hydrolysis. This is why injectable glutathione produces dramatically different clinical results than oral supplementation.

INTRAVENOUS (IV)

~100%

Gold standard · Immediate systemic availability · Requires clinical setting for initial doses

SUBCUTANEOUS (SC)

~85–90%

Excellent · At-home use with Apex pen · Slower absorption, sustained release · Preferred for routine use

NEBULIZED (INHALED)

~60–70%

Pulmonary-specific · Used for lung conditions, Parkinson's symptom management

02 / RESEARCH HISTORY

Development Timeline

1888

Glutathione first isolated by J. de Rey-Pailhade from yeast. Named "philothion" (sulfur-loving). The active thiol group identified as central to its biological activity.

1921

Frederick Gowland Hopkins (Nobel Prize, 1929) establishes glutathione's structure and ubiquity in living cells. Recognizes it as a fundamental redox molecule — present in nearly all aerobic organisms.

1950s–1970s

GSH's role in drug metabolism established. Phase II detoxification: GSH conjugates with toxic metabolites, heavy metals, and xenobiotics via glutathione-S-transferase (GST) → making them water-soluble for urinary excretion. Liver as the central GSH reservoir for systemic detoxification.

1980s–1990s

IV glutathione enters clinical use for chemotherapy side effect management, acetaminophen overdose treatment (the gold standard antidote: NAC replenishes GSH), and liver disease. Italian researchers pioneer IV glutathione for Parkinson's disease symptom management.

2000s–Present

Liposomal and SC glutathione formulations developed for at-home use. Anti-aging applications studied: GSH decline correlated with accelerated aging, neurodegeneration, and cancer susceptibility. Skin brightening mechanism (melanin inhibition) documented in Asian clinical trials. NAD+ + Glutathione combination emerges as core longevity protocol.

03 / BENEFITS & MECHANISMS

Research-Supported Effects

01

Master Antioxidant — Cellular ROS Neutralization

GSH is the primary intracellular antioxidant — directly neutralizing superoxide, hydroxyl radicals, and hydrogen peroxide. Also regenerates vitamins C and E from their oxidized forms (recycling the antioxidant network). When GSH is depleted, the entire antioxidant cascade collapses — oxidative damage accelerates exponentially. Restoring GSH supports every other antioxidant system simultaneously.

02

Phase II Liver Detoxification

The liver uses GSH as the primary conjugation substrate for Phase II detox. Glutathione-S-transferase (GST) enzymes attach GSH to lipophilic toxins (environmental chemicals, drug metabolites, heavy metals) → forming water-soluble conjugates → excreted in bile or urine. Low GSH = compromised detoxification capacity = toxin accumulation. IV/SC GSH rapidly restores hepatic detox capacity.

03

Mitochondrial Protection & Energy

Mitochondria are the primary site of ROS production — and mitochondrial GSH (mGSH) is the only antioxidant defense inside the mitochondria. mGSH depletion causes mitochondrial dysfunction, reduced ATP production, and accelerated cell death. GSH supplementation preferentially replenishes mGSH, protecting the energy-producing organelle and sustaining cellular energy output.

04

Skin Brightening — Melanin Inhibition

GSH inhibits tyrosinase — the rate-limiting enzyme in melanin synthesis. Less tyrosinase activity = less melanin production = lighter, more even skin tone. Simultaneously, GSH shifts melanin synthesis from dark eumelanin toward lighter pheomelanin. Multiple Asian clinical trials confirm: IV/SC glutathione produces measurable skin lightening and reversal of hyperpigmentation at consistent doses. One of the most clinically validated cosmetic benefits of any peptide.

05

Immune Modulation & Antiviral

GSH is essential for lymphocyte proliferation and T-cell activation — immune cells have among the highest GSH requirements of any cell type. Low GSH = impaired immune response. GSH also has direct antiviral activity: inhibits viral replication by preventing viral protein disulfide bond formation. Relevant for HIV, influenza, and herpes virus management. Pairs powerfully with Thymosin Alpha-1 for comprehensive immune support.

06

Neurological Protection — Parkinson's & Cognitive

The substantia nigra (Parkinson's-affected brain region) has the highest GSH concentration in the brain — and the greatest GSH depletion in Parkinson's patients. IV glutathione (Perlmutter protocol) shows symptom improvement in early Parkinson's. Broader neuroprotection: GSH protects neurons from oxidative stress, maintains myelin integrity, and supports neurotransmitter synthesis.

04 / RECONSTITUTION

Vial Preparation

STANDARD VIAL — 600mg (SC/IV USE)

600mg vial + 3.0 mL (300 units) bacteriostatic water

Concentration: 2mg per unit (2,000 mcg per unit)

NOTE: Glutathione is mg-scale dosing — not mcg-scale like peptides

DOSE	mg	UNITS ON SYRINGE	VOLUME
LOW (SC)	200mg	100 units	1.0 mL
STANDARD (SC)	400mg	200 units	2.0 mL
HIGH (SC)	600mg (full vial)	300 units	3.0 mL
IV PUSH	600–1,200mg	Diluted in 50–100mL NS	Clinical setting required

⚠ SC Volume Consideration: SC injection of 2–3mL is a larger volume than typical peptide injections. Split into 2 injection sites if uncomfortable (1mL each). Use a slow injection rate — GSH SC can cause mild burning at injection site due to acidity. Can be pH-adjusted with sodium bicarbonate by compounding pharmacy.

⚠ Stability Critical: Reconstituted glutathione oxidizes rapidly. Use within 1–2 hours of reconstitution for maximum potency. Some pharmacies supply pre-reduced glutathione with stabilizers — follow pharmacy label for shelf life. Protect from air exposure — draw dose immediately before injection.

Storage: Lyophilized powder: refrigerate at 2–8°C, stable 12 months. Light sensitive — store in foil or dark vial. Do NOT freeze reconstituted glutathione. Ideal approach: reconstitute immediately before each injection.

05 / DOSING PROTOCOL

Dose Ranges

PROTOCOL	DOSE	FREQUENCY	INDICATION
MAINTENANCE	200–400mg SC / 2–3×/week	2–3× weekly	General antioxidant support, anti-aging, skin brightening maintenance
STANDARD	400–600mg SC / daily	Daily SC	Active detox protocol, liver support, skin brightening induction, immune restoration
INTENSIVE IV	600–1,200mg IV push	1–3×/week	Clinical protocols: Parkinson's, heavy metal detox, chemotherapy support, severe oxidative stress
SKIN BRIGHTENING	600mg SC or IV / 3×/week	3× weekly × 12–24 weeks	Melanin inhibition protocol. Tyrosinase inhibition builds over weeks — results visible at 8–16 weeks.

      NAD+ + Glutathione Protocol: The most powerful anti-aging injection protocol: NAD+ 500mg IV/SC (cellular energy + sirtuin activation) + Glutathione 600mg IV/SC (master antioxidant + detox). Run sequentially on the same visit — NAD+ first, then GSH. The two compounds are synergistic: NAD+ drives cellular energy production (which generates ROS) and GSH neutralizes the ROS produced. They are the yin and yang of cellular health.
    

06 / TIMING & ADMINISTRATION

Injection Protocol

TIMING

No fasting requirement. Morning preferred — supports liver detoxification activity which peaks in early AM. Evening acceptable. Avoid injection immediately post-intense exercise (oxidative stress is high — give GSH 1–2h to circulate before heavy training).

SC INJECTION TECHNIQUE

Use a larger gauge needle (25–27g) for GSH given larger volumes. Inject slowly (30+ seconds) to minimize burning. Abdominal SC preferred — larger tissue volume accommodates 2–3mL comfortably. Can split dose across two sites (e.g., bilateral abdomen) for volumes over 2mL.

NEBULIZATION PROTOCOL

For respiratory/neurological indications: dilute 600mg GSH in 3mL sterile saline. Nebulize over 15–20 min via standard aerosol mask. Pulmonary delivery is direct and avoids systemic dilution. Used in Parkinson's, chronic lung disease, and respiratory viral infections.

POST-EXERCISE GSH CRASH

Intense exercise acutely depletes GSH by 30–50% in muscle tissue. This is normal and contributes to training adaptation — but chronic depletion impairs recovery. Post-workout GSH injection (1–2h after training) accelerates GSH repletion, reduces muscle oxidative damage, and speeds recovery.

ALCOHOL / ACETAMINOPHEN

Both alcohol and acetaminophen heavily deplete hepatic GSH. GSH 400–600mg SC the morning after heavy alcohol consumption dramatically reduces hangover severity and liver oxidative stress. Pre/post acetaminophen dosing (within safe limits) with GSH reduces hepatotoxic metabolite accumulation.

PRECURSOR STACK

NAC (N-acetylcysteine) oral supplementation provides the rate-limiting precursor (cysteine) for endogenous GSH synthesis. NAC 600mg oral 2×/day + direct GSH injection = maximal approach combining precursor supply with exogenous replacement.

07 / BIOMARKER MONITORING

Recommended Lab Panel

GLUTATHIONE STATUS — DIRECT

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
Whole Blood GlutathioneGSH/GSSG ratio	CLINICALVaries (lab-specific)	OPTIMALGSH/GSSG >10:1	Direct measurement of reduced vs. oxidized glutathione. The ratio is more informative than absolute levels. <5:1 indicates significant oxidative stress.
Erythrocyte GSHred blood cell glutathione	CLINICAL1,000–1,500 µg/gHb	OPTIMAL>1,200 µg/gHb	Most reliable blood-based GSH measure. RBCs have no mitochondria — GSH here reflects systemic antioxidant status. Should improve with consistent SC supplementation.

OXIDATIVE STRESS — INDIRECT MARKERS

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
8-OHdG8-hydroxy-2-deoxyguanosine (urine)	CLINICAL<15 ng/mg Cr	OPTIMAL<5 ng/mg Cr	Oxidative DNA damage marker — primary readout of systemic oxidative stress. Should decrease significantly with GSH supplementation.
Malondialdehyde (MDA)lipid peroxidation	CLINICAL<2.5 µmol/L	OPTIMAL<1.0 µmol/L	Lipid peroxidation marker — ROS damage to cell membranes. Decreasing MDA confirms GSH is protecting cellular membranes from oxidative attack.
hs-CRPC-reactive protein	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L	Oxidative stress and inflammation are linked — GSH reduction of ROS should also reduce NF-κB activation and downstream CRP production.

LIVER FUNCTION

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
ALT / ASTliver enzymes	CLINICALALT <40 / AST <40 U/L	OPTIMALALT <20 / AST <20 U/L	Should improve or normalize with GSH — hepatoprotective effect via restored detoxification capacity. Track at 8-week intervals.
GGTgamma-glutamyltransferase	CLINICAL<55 U/L (M) / <38 U/L (F)	OPTIMAL<20 U/L	GGT is elevated when GSH turnover is high (body working to replenish depleted GSH). Normalizing GGT indicates restored GSH sufficiency. Excellent GSH status marker.

08 / CYCLE PROTOCOL

Administration Schedule

CYCLE LENGTH

Ongoing — Safe for Chronic Use

CONTINUOUS USE

Unlike most peptides, glutathione is an endogenous molecule with no known tolerance, suppression of endogenous synthesis, or adverse effects from chronic use at therapeutic doses. It is safe for indefinite maintenance use. Most patients benefit from 2–3×/week as a minimum maintenance frequency.

INTENSIVE LOADING PHASE

For significant depletion states (liver disease, chemotherapy, heavy metal toxicity, post-COVID): daily 600mg SC or IV × 4–8 weeks. Then transition to 2–3×/week maintenance. Loading saturates tissue stores before transitioning to maintenance.

SKIN BRIGHTENING TIMELINE

Tyrosinase inhibition accumulates over weeks. Visible results at 8–16 weeks of consistent 3×/week 600mg dosing. Maintenance 2×/week sustains results. Concurrent topical vitamin C amplifies the brightening effect.

LONGEVITY PROTOCOL

NAD+ 500mg + GSH 600mg 1–2×/week IV or SC. The ultimate cellular health maintenance protocol — energy production + antioxidant defense. Add MOTS-c 5mg AM daily for mitochondrial efficiency. This three-compound stack is the Apex longevity foundation protocol.

REQUIRES

Reconstitution with sterile or bacteriostatic water · Apex V3 Pen · Refrigeration · Fresh reconstitution recommended per-dose for maximum potency

⚠ Research reference only. Injectable glutathione is available from compounding pharmacies and used extensively in clinical settings. IV administration should be performed by trained medical professionals for initial doses. Consult a qualified medical provider before use.